Paola Fioretto discusses possible underlying mechanisms of the nephroprotective effects of SGLT2i, as observed in large clinical trials.
Dr. Herrington summarizes key randomized data from completed large placebo-controlled SGLT2-inhibitor trials and describes ongoing SGLT2i trials in diabetes, renal and HF populations.
Prof. Agarwal discusses the current standard of care in diabetic kidney disease and the evidence of how SGLT2 inhibitors can contribute to protect the kidney in DKD.
Slides as educational service to PACE members and meeting participants
Slides as educational service to PACE members and meeting participants
Slides as educational service to PACE members and meeting participants